Insurers cut back GLP-1 coverage as demand soars: Found study

As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

91 Top Dividend Stocks From Around the World

What is Ozempic and why is B.C. cracking down on sales of the drug to Americans?

Ozempic: How the Diabetes Drug Works and Why It's Such a Big Deal for Weight Loss - WSJ

As the market for new weight loss drugs soars, people with diabetes pay the price

The Impact of GLP-1 Coverage and Spend on Pharmacy Benefits Costs - New

Lilly weight-loss drug Zepbound new US prescriptions surpass

Weight loss drugs like Ozempic could upend industries including air travel - The Washington Post

Demography Is Destiny in Africa - Edward Conard

The Rise of GLP-1 Receptor Agonists and Coverage Challenges

GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

The Rise of GLP-1 Receptor Agonists and Coverage Challenges